Multi-Omic, Clinomic and Digitomic Attributes of Major Depression for Integrative Analytics

Major Depressive Disorder Clinical Trial

Official title:

Multi-Omic, Clinomic and Digitomic Attributes of Major Depression for Integrative Analytics: the MACADAMIA Pilot Study

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05910957
• Other study ID #: 23-002931
• Status: Enrolling by invitation
• Start date: August 2, 2023
• Est. completion date: October 2024

Study information

• Verified date: August 2023
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this research is to see if information from blood and data from smartwatches can be combined to help diagnose depression and determine if transitions between active depression and treated depression can be predicted.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 40
• Est. completion date: October 2024
• Est. primary completion date: October 2024
• Gender: All
• Age group: 20 Years to 62 Years

Eligibility

Inclusion Criteria:

• Participated in the BROWNIE study.

• DSM-5 diagnostic criteria are met for unipolar, non-psychotic MDD (excluding controls).

• A score of > 10 on the QIDS-C and QIDS-SR (equivalent to 13 or greater on HAM-D17) given that when medication exceeds the effect of placebo in primary care participants have a HAM-D17 >12 (excluding controls).

• Antidepressant treatment is deemed appropriate by a study clinician (excluding controls).

• Smart watch wear time is at least 70% during their participation in the BROWNIE study.

Exclusion Criteria:

• Subjects with medical contraindications that preclude treatment with study drugs will be excluded.

• Patients with schizophrenia, schizoaffective disorder, or who have bipolar I or II disorder (or another specified or unspecified bipolar spectrum disorder) will be excluded because they have a primary psychiatric condition that requires a different initial treatment.

• Subjects currently on antidepressant medication with subtherapeutic results in terms of depression management will undergo a medication taper and discontinuation prior to initiation of a new study medication. The subject will be closely monitored by the study clinician during the medication taper and discontinuation phase. The medication taper is left up to the study clinician's discretion. Study subjects who cannot be safely tapered from their medication or experience adverse effects during the taper will be excluded from the study.

• Subjects who have an active substance use disorder will be excluded. An active substance use disorder will be defined as meeting DSM-5 diagnostic criteria for any active substance use disorder. Persons meeting DSM-5 diagnostic criteria for a substance use disorder in full remission (>12 months) and a negative urine drug of abuse screen at the screening visit or before the baseline study visit will be considered eligible. Persons with a positive urine drug of abuse screen may participate in the study if they do not meet DSM-5 diagnostic criteria for a substance use disorder.

• Subjects unable to give informed consent or who are unwilling or unable to comply with study requirements are excluded.

• Pregnant subjects will be excluded.

• Subjects who are currently breastfeeding and who plan to continue breastfeeding will be excluded.

• Subjects who are psychiatrically hospitalized or in a mental health crisis requiring urgent care or psychiatric hospitalization.

• Study subjects currently on antipsychotic medications (e.g., typical, and atypical antipsychotic drugs) taken for primary psychotic illness or affective psychosis will be excluded.

• Study subjects taking mood stabilizing agents (e.g., lithium, carbamazepine, valproate, lamotrigine, gabapentin, or other anticonvulsants) taken specifically for bipolar spectrum disorders are not eligible for participation.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Locations

Country	Name	City	State
United States	Mayo Clinic Florida	Jacksonville	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Quick Inventory of Depressive Symptoms-Clinician Rated (QIDS-CR) scale	The Quick Inventory of Depressive Symptoms-Clinician Rated is used for rating the severity of depressive symptoms. Possible scores range from 0 to 27, with higher scores indicating greater severity of depression.	Baseline, 4 weeks, and 8 weeks
Secondary	Change in Hamilton Depression Rating Scale	The Hamilton Depression Rating Scale is used for rating the severity of depressive symptoms. Possible scores range from 0 to 50, with higher scores indicating greater severity of depression.	Baseline, 4 weeks, and 8 weeks

External Links

•   Mayo Clinic Clinical Trials